AstraZeneca, Jubilant Biosys Join Hands For Leads In Neuroscience
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Collaborative research between Indian and multinational drug companies gained further ground as Jubilant Biosys signed an agreement with AstraZeneca for delivering novel drug candidates to strengthen its preclinical pipeline. Based out of Bangalore, Jubilant Biosys is the research arm of Jubilant Organosys
You may also be interested in...
AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.
AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.
With Too Much To Handle, Indian Pharma Companies Face Uphill Task In Their Quest To Clinch New Contracts, Grow Further
MUMBAI - Compulsions for large-scale investments, paucity of medicinal chemistry skills that can be valued from an intellectual property standpoint and pressures of sustaining multiple portfolio-based partnerships for discovering new compounds are seen as some of the biggest challenges faced by the Indian pharmaceutical industry, executives at top Indian companies told the PharmAsia Summit in San Francisco Oct. 27